IntoCell, Inc. (KOSDAQ:287840)

Market Cap	711.57B
Revenue (ttm)	1.68B -39.8%
Net Income	-10.45B
EPS	-754.98
Shares Out	15.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	92,756
Average Volume	142,687
Open	47,200
Previous Close	47,600
Day's Range	46,650 - 48,950
52-Week Range	21,400 - 74,900
Beta	n/a
RSI	48.44
Earnings Date	n/a

About IntoCell

IntoCell, Inc. develops protein-drug conjugates for the treatment of cancer. It develops antibody drug conjugates (ADC), fusion albumin drug conjugates, and triple conjugates. The company also develops B7-H3 ADC, which is in preclinical Phase for the treatment of solid cancers, as well as HER3 ADC, 5T4 ADC, and PSMA ADC for solid cancers. In addition, it develops Ortho-Hydroxy Protected Aryl Sulfate (OHPAS), a novel self-immolative group that designs to incorporate various functional groups for linking targeting moieties; and OHPASM Linker-toxi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 287840

Financial Performance

In 2024, IntoCell's revenue was 2.91 billion, an increase of 79.72% compared to the previous year's 1.62 billion. Losses were -9.91 billion, -40.91% less than in 2023.